Complement activation and inhibition in experimental models of arthritis

Molecular Immunology

Volumn 36, Issue 13-14, 1999, Pages 905-914

  Linton, Stuart M ^a   Morgan, B Paul ^a  

^a Univ W   (United Kingdom)

Author keywords

Collagen induced arthritis; Complement; CR1; Rheumatoid arthritis

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTHRITIS; AUTOIMMUNITY; BACTERIAL CELL WALL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE TARGETING; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK BENEFIT ANALYSIS;

ANIMALS; ARTHRITIS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BACTERIA; CELL WALL; COBRA VENOMS; COLLAGEN; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; MICE; RECEPTORS, COMPLEMENT 3B;

EID: 0033390443     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(99)00113-3     Document Type: Conference Paper

References (94)

1. Andersson M., Goldschmidt T.J., Michaelsson A., et al. T-cell receptor Vβ haplotype and complement component C5 play no significant role for the resistance to collagen-induced arthritis in the SWR mouse. Immunology. 73:1991;191-196.
2. Apparailly F., Verwaerde C., Jacquet C., et al. Adenovirus-mediated transfer of viral IL10 gene inhibits murine to collagen-induced arthritis. J. Immunol. 160:1998;5213-5220.
3. Ashkenazi A., Chamow S.M. Immunoadhesins as research tools and therapeutic agents. Curr. Opin. Immunol. 9:1997;195-200.
4. Athanasou N.A., Quinn J., Heryet A., et al. The immunohistology of synovial lining cells in normal and in inflamed synovium. J. Pathol. 155:1988;133-142.
5. Banerjee S., Anderson G.D., Luthra H.S., et al. Influence of complement C5 and Vβ T-cell receptor mutations on susceptibility to collagen-induced arthritis in mice. J. Immunol. 142:1989;2237-2243.
6. Brauer R., Kette H., Henzgen S., et al. Influence of cyclosporin A on cytokine levels in synovial fluid and serum of rats with antigen-induced arthritis. Agents Actions. 41:1994;96-98.
7. Breitner S., Storkel S., Reichel W., et al. Complement components C1q, C1r/C1 s, and C1inh in rheumatoid arthritis. Arthritis Rheum. 38:1995;492-498.
8. Brodeur J.P., Ruddy S., Schwartz L.B., et al. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum. 34:1991;1531-1537.
9. Cinader B., Dubiski S., Wardlaw A.C. Distribution, inheritance, and properties of an antigen MUB1, and its relation to haemolytic complement. J. Exp. Med. 120:1964;897-902.
10. Cooke T.D., Hurd E.R., Ziff M., et al. The pathogenesis of chronic inflammation in experimental antigen induced arthritis - II: preferential localization of antigen-antibody complexes to collagenous tissues. J. Exp. Med. 135:1972;323-338.
11. Cooke T.D., Hurd E.R., Jasin H.E. Identification of immunoglobulins and complement in rheumatoid articular collagenous tissues. Arthritis Rheum. 18:1975;541-551.
12. Courtenay J.S., Dallmann M.J., Dayan A.D., et al. Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 283:1980;666-668.
13. Cromartie W.J., Craddock J.C., Scwab J.H. Arthritis in rats after systemic injection of streptococcal cell or cell walls. J. Exp. Med. 146:1977;1585-1602.
14. Dalldorf F.G., Cromartie W.J., Anderle S.J., et al. Relation of experimental arthritis to the distribution of streptococcal cell wall fragments. Am. J. Path. 100:1980;383.
15. Daniels R.H., Williams B.D., Morgan B.P. Stimulation of human rheumatoid synovial cell by non-lethal complement membrane attack. Immunology. 69:1990;237-242.
16. Davies M.E., Horner A., Loveland B.E. Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint diseases. Scand. J. Rheumatol. 23:1994;316-321.
17. DeShazo C.V., Henson P.M., Cochrane C.G. Acute immunologic arthritis in rabbits. J. Clin. Invest. 51:1972;50-57.
18. Doherty M., Richards N., Hornby J., et al. Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis and crystal associated arthropathy. Ann. Rheum. Dis. 47:1988;190-197.
19. Dumonde D.C., Glynn L.E. The production of arthritis in rabbits by an immunological reaction of fibrin. Br. J. Exp. Path. 43:1962;373.
20. Evans C.H., Ghivizzani S.C., Kang R., et al. Gene therapy for rheumatic diseases. Arthritis Rheum. 42:1999;1-16.
21. Fava R.A., Dalmasso A.P., Kim Y., et al. Critical role of peripheral blood phagocytes and the involvement of complement in tumor necrosis factor enhancement of passive collagen-arthritis. Clin. Exp. Immunol. 94:1993;261-266.
22. Fearon D.T. Cellular responses for fragments of the third component of complement. Immunol. Today. 5:1984;105-109.
23. Firestein G.S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? Arthritis Rheum. 39:1996;1781-1790.
24. Fujita M., Mishima M., Iwabuchi K., et al. A study on type II collagen-induced arthritis in allogeneic bone marrow chimaeras. Immunology. 66:1989;422-427.
25. Gaede K.I., Baumeister E., Heesemann J. Decomplementation by cobra venom factor suppresses Yersinia-induced arthritis in rats. Infect. Immunity. 63:1995;3697-3701.
26. Goodfellow R.M., Williams A.S., Levin J.L., et al. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin. Exp. Immunol. 110:1997;45-52.
27. Goodfellow, R.M., Williams, A.S., Levin, J.L., et al., 1999. Soluble complement receptor 1 (SCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin. Exp. Immunol. In press.
28. Guc D., Gulati P., Lemercier C., et al. Expression of the components and regulatory proteins of the alternative complement pathway and the mebrane attack complex in normal and diseased synovium. Rheumatol. Int. 13:1993;139-146.
29. Hamann J., Wishaupt J.O., van Lier R.A.W. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum. 42:1999;650-658.
30. Harris C.L., Linton S., Morgan B.P. Generation of complement inhibitor-IgG fusion proteins as anti-complement therapeutic reagents. Mol. Immunol. 36:1999;315.
31. Hogasen K., Mollnes T.E., Harboe M., et al. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J. Rheumatol. 22:1995;24-28.
32. x-glycosylated complement inhibitory protein. Science. 285:1999;595-599.
33. Hunneyball I.M. The use of experimental arthritis in the rabbit for the development of antiarthritic drugs. Adv. Inflamm. Res. 7:1984;249-255.
34. Isaacs J.D. Immunoadhesins for immunomodulation of autoimmune and rheumatic disease. Br. J. Rheumatol. 36:1997;305-309.
35. Itoh J., Nose M., Fujita T., et al. Expression of decay-accelerating factor is reduced on hyperplastic synovial lining cells in rheumatoid synovitis. Clin. Exp. Immunol. 83:1991;364-368.
36. Jahn B., von Kempis J., Kramer K.L., et al. Interaction of the terminal complement components C5b-9 with synovial fibroblasts-binding to the membrane surface leads to increased levels in collagenase-specific messenger RNA. Immunology. 78:1993;329-334.
37. Jose P.J., Moss I.K., Maini R.N., et al. Measurement of the chemotactic complement fragments C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann. Rheum. Dis. 49:1990;747-752.
38. Kalli K.R., Hsu P., Fearon D.T. Therapeutic uses of recombinant protein inhibitors. Spring. Sem. Immunopath. 15:1994;417-433.
39. Kemp P.A., Spragg J.H., Brown J.C., et al. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neo-antigen specific monoclonal antibodies. J. Clin. Lab. Immunol. 37:1992;147-162.
40. Kerwar S.S., Bauman N., Oronsky A.L., et al. Studies on type II collagen-induced polyarthritis in rats: effect of complement depletion. Journal of Immunopharmacology. 3:(3&4):1982;323-337.
41. Keystone E.C., Schorlemmer H.U., Pope C., et al. Zymosan-induced arthritis. Arthritis Rheum. 20:1977;1396-1401.
42. Kim Y.U., Kinoshita H., Molina D., et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J. Exp. Med. 181:1995;151-157.
43. Klareskog L., Holmdahl R., Larsson E., et al. Role of T-lymphocytes in collagen-induced arthritis in rats. Clin. Exp. Immunol. 51:1983;117-125.
44. Koga T., Kakimoto K., Hirofuji T., et al. Acute joint inflammation in mice after systemic injection of the cell wall, its peptidoglycan, and chemically defined peptidoglycan subunits from various bacteria. Infect. Immunity. 50:1985;27-34.
45. Konttinen Y.T., Ceponis A., Meri S., et al. Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann. Rheum. Dis. 55:1996;888-894.
46. Kourounakis L., Nelson N.A., Kupusta M.S. The effect of a cobra venom factor on complement and adjuvant-induced disease in rats. Arthritis Rheum. 16:1973;71-79.
47. Langer R. Drug delivery and targeting. Nature. 392:1998;S5-S10.
48. Lasky L.A. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science. 258:1992;964-969.
49. Le C.H., Nicolson A.G., Morales A., et al. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumour necrosis factor a receptor gene. Arthritis Rheum. 40:1997;1662-1669.
50. Linton S., Dodd I., Smith R., et al. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen arthritis in the rat. Mol. Immunol. 36:1999;306.
51. Lublin D.M., Atkinson J.P. Decay accelerating factor and membrane cofactor protein. Curr. Top. Microbiol. Immunol. 153:1989;123-145.
52. Makrides S.C., Nygren P.A., Andrews B., et al. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. Journal of Pharmacology and Experimental Therapeutics. 277:1996;534.
53. Medof M.E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay accelerating factor (DAF) into their membranes. J. Exp. Med. 160:1984;1558-1578.
54. Medof M.E., Nagarajan S., Tykocinski M.L. Cell-surface engineering with GPI-anchored proteins. FASEB J. 10:1996;574-586.
55. Medof M.E., Walter E.I., Rutrers J.L., et al. Identification of the complement decay accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. 165:1987;848-864.
56. Meri S., Morgan B.P., Davies A., et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 71:1990;1-8.
57. Mizuno M., Nishikawa K., Goodfellow R., et al. The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats. Arthritis Rheum. 40:1997;527-533.
58. Mollnes T.E., Lea T., Mellbye O.J., et al. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum. 29:1986;715-721.
59. Mori L., de Libero G. Genetic control of susceptibility to collagen-induced arthritis in T-cell receptor β-chain transgenic mice. Arthritis Rheum. 41:1998;256-262.
60. Morgan K., Clague R.B., Shaw M.J., et al. Native type II collagen-induced arthritis in the rat. Arthritis Rheum. 24:1981;1356-1362.
61. Morgan B.P., Daniels R.H., Williams B.D. Measurement of terminal complement complexes in rheumatoid arthritis. Clin. Exp. Immunol. 73:1988;473-478.
62. Morgan B.P., Daniels R.H., Watts M.J. In vivo and in vitro evidence of cell recovery from complement attack in rheumatoid synovium. Clin. Exp. Immunol. 73:1988;467-472.
63. Morgan B.P., Harris C.L. Complement Regulatory Proteins. 1999;Academic Press, San Diego.
64. Moxley G., Ruddy S. Elevated C3 anaphylotoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 28:1985;1089-1095.
65. x moieties. J. Immunol. 162:1999;4952-4959.
66. Myers L.K., Rosloniec E.F., Cremer M.A., et al. Collagen-induced arthritis, an animal model of autoimmunity. Life Sciences. 61:1997;1861-1878.
67. Oleesky D.A., Daniels R.H., Williams B.D., et al. Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions. Clin. Exp. Immunol. 84:1991;250-255.
68. Peakman M., Lobo-Yeo A., Senaldi G.L., et al. Quantification of C3 d in biological fluids by an enzyme-linked immunosorbent assay. J. Immunol. Meth. 104:1987;51-56.
69. Pearson C.M., Wood F.D. Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant - I: general clinical and pathological characteristics and some modifying factors. Arthritis Rheum. 2:1959;440-448.
70. Perrin L.H., Nydegger U.E., Zubler R.H., et al. Correlation between levels of breakdown products of C3, C4, and properdin factor B in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 20:1977;647-652.
71. Quigg R.J., Kozono Y., Berthiaume D., et al. Blockade of antibody-induced glomerulonephritis with CrrY-Ig, a soluble murine complement inhibitor. J. Immunol. 160:1998;4553-4560.
72. Reife R.A., Loutis N., Watson W.C., et al. SWR mice are resistant to collagen-induced arthritis but produce potentially arthritogenic antibodies. Arthritis Rheum. 34:1991;776-781.
73. Ruddy S., Colten H.R. Rheumatoid arthritis: biosynthesis of complement proteins by synovial tissues. N.E.J.M. 290:1974;1284-1288.
74. Sadallah S., Lach E., Lutz H.U., et al. CR1, CD35 in synovial fluid from patients with inflammatory joint diseases. Arthritis Rheum. 40:1997;520-526.
75. Sanders M.E., Kopicky J.A., Wigley F.M., et al. Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy. J. Rheumatol. 13:1986;1028-1034.
76. Santos L.L., Morand E.F., Hutchinson P., et al. Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. Clin. Exp. Immunol. 107:1997;248-253.
77. Schultz D.R. Induced deficiencies in animals and man. Prog. Allergy. 39:1986;101-122.
78. Schwab J.H., Allen J.B., Anderle S.K., et al. Relationship of complement to experimental arthritis induced in rats with streptococcal cell walls. Immunology. 46:1982;83-88.
79. Seya T., Holers V., Atkinson J.P. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b binding protein (C4bp) and decay accelerating factor (DAF). J. Immunol. 135:1985;2661-2667.
80. Spinella D.G., Jeffers J.R., Reife R.A., et al. The role of C5 and T-cell receptor Vβ genes in susceptibility to collagen-induced arthritis. Immunogenetics. 34:1991;23-27.
81. Tarkowski A., Trollmo C., Seifert P.S., et al. Expression of decay accelerating factor on synovial lining cells in inflammatory and degenerative arthritides. Rheumatol. Int. 12:1992;201-205.
82. Taurog J.D., Sandberg G.P., Mahowald M.L. The cellular basis of adjuvant arthritis - II. Cell Immunol. 80:1983;198-204.
83. Trentham D.E., Townes A.S., Kang A.H. Autoimmunity to type II collagen: an experimental model of arthritis. J. Exp. Med. 146:1977;857-868.
84. Trentham D.E. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum. 25:1982;911-916.
85. van den Broek M.F., van Bruggen M.C., Stimpson S.A., et al. Flare up reaction of streptococcal cell wall-induced arthritis in Lewis and F344 rats: the role of T lymphocytes. Clin. Exp. Immunol. 79:1990;297-306.
86. Van Lent P.L.E.M., van den Bersselaar L.A.M., van den Hoek A.E.M. Cationic immune complex arthritis in mice - a new model. Am. J. Path. 140:1992;1451-1461.
87. Vogel C.W., Bredehorst R., Fritzinger D.C., et al. Structure and function of cobra venom factor, the complement-activating protein in cobra venom. Singh B.R., Tu A.T. Natural Toxins II. 1996;97-114 Plenum Press, New York.
88. Walz D.T., DiMartino M.J., Flagiello J., et al. The effect of a complement (C) depleter and antiarthritic agents on C levels and inflammation in adjuvant arthritis (AA) rats. Fed. Proc. 32:(1):1973;752.
89. Wang Y., Rollins S.A., Madri J.A., et al. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA. 92:1995;8955-8959.
90. Watson W.C., Brown P.S., Pitcock J.A., et al. Passive transfer studies with type II collagen antibody in B10.D2/old and new line and C57bl/6 normal and beige (Chediak-Higashi) strains: evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive arthritis. Arthritis Rheum. 30:1987;460-465.
91. Weinblatt M.E., Kremer J.M., Bankhurst A.D. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N.E.J.M. 340:1999;253-259.
92. Williams A.S., Camilleri J.P., Williams B.D. Suppression of adjuvant-induced arthrits by liposomally conjugated methotrexate in the rat. Br. J. Rheumatol. 33:1994;530-533.
93. Williams A.S., Camilleri J.P., Goodfellow R.M., et al. A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen-induced arthritis. Br. J. Rheumatol. 35:1996;719-724.
94. Williams R.O., Feldmann M., Maini R. Anti TNF ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA. 89:1992;9784-9788.